[go: up one dir, main page]

MX2018010445A - Anticuerpos especificos del receptor de poliovirus humano (rvp). - Google Patents

Anticuerpos especificos del receptor de poliovirus humano (rvp).

Info

Publication number
MX2018010445A
MX2018010445A MX2018010445A MX2018010445A MX2018010445A MX 2018010445 A MX2018010445 A MX 2018010445A MX 2018010445 A MX2018010445 A MX 2018010445A MX 2018010445 A MX2018010445 A MX 2018010445A MX 2018010445 A MX2018010445 A MX 2018010445A
Authority
MX
Mexico
Prior art keywords
pvr
antibodies specific
poliovirus receptor
human poliovirus
receptor
Prior art date
Application number
MX2018010445A
Other languages
English (en)
Inventor
Mandelboim Ofer
S Kaynan Noa
Tsukerman Pinchas
Jonjic Stipan
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of MX2018010445A publication Critical patent/MX2018010445A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invención proporciona anticuerpos monoclonales que reconocen el receptor de poliovirus (RVP) e inhiben su enlazamiento a un inmuno-receptor de células T con dominios de lg y ITIM (TIGIT). La presente invención proporciona además composiciones farmacéuticas que comprenden los anticuerpos y métodos para su uso en inmunoterapia de cáncer, tratamiento de infecciones y en diagnósticos.
MX2018010445A 2016-03-01 2017-02-28 Anticuerpos especificos del receptor de poliovirus humano (rvp). MX2018010445A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301727P 2016-03-01 2016-03-01
US201662364924P 2016-07-21 2016-07-21
PCT/IL2017/050256 WO2017149538A1 (en) 2016-03-01 2017-02-28 Antibodies specific to human poliovirus receptor (pvr)

Publications (1)

Publication Number Publication Date
MX2018010445A true MX2018010445A (es) 2019-10-17

Family

ID=58410405

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018010445A MX2018010445A (es) 2016-03-01 2017-02-28 Anticuerpos especificos del receptor de poliovirus humano (rvp).
MX2022014867A MX2022014867A (es) 2016-03-01 2018-08-29 Anticuerpos especificos del receptor de poliovirus humano (rvp).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022014867A MX2022014867A (es) 2016-03-01 2018-08-29 Anticuerpos especificos del receptor de poliovirus humano (rvp).

Country Status (15)

Country Link
US (3) US10906987B2 (es)
EP (2) EP4043492A1 (es)
JP (1) JP6966176B2 (es)
KR (2) KR20250065434A (es)
CN (1) CN109071666B (es)
AU (2) AU2017228055B2 (es)
BR (1) BR112018067522A2 (es)
CA (1) CA3015619A1 (es)
CO (1) CO2018010538A2 (es)
ES (1) ES2903280T3 (es)
IL (2) IL261200B2 (es)
MX (2) MX2018010445A (es)
RU (1) RU2756275C2 (es)
SG (1) SG11201807437XA (es)
WO (1) WO2017149538A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11098130B1 (en) 2015-08-03 2021-08-24 Tasrif Pharmaceutical, LLC Antibodies and antibody fragments against the CD155 receptor and methods of use thereof
US10906987B2 (en) 2016-03-01 2021-02-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (PVR)
WO2018229163A1 (en) * 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
WO2019102456A1 (en) 2017-11-27 2019-05-31 University Of Rijeka Faculty Of Medicine Immunotoxins for treating cancer
EP3790900A1 (en) 2018-05-09 2021-03-17 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Antibodies specific to human nectin4
BR112021003156A2 (pt) 2018-08-23 2021-05-11 Seagen, Inc. composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit.
US11672826B2 (en) 2018-08-30 2023-06-13 HCW Biologics, Inc. Methods of treating aging-related disorders
JP7397874B2 (ja) 2018-08-30 2023-12-13 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
KR20210069639A (ko) 2018-08-30 2021-06-11 에이치씨더블유 바이올로직스, 인크. 단일-사슬 키메라 폴리펩타이드 및 이의 용도
CN113301954B (zh) * 2019-01-13 2024-08-27 耶路撒冷希伯来大学伊森姆研究发展有限公司 特异性针对人类连接蛋白-2的抗体
CN114269903B (zh) 2019-06-21 2025-11-25 免疫生物公司 多链嵌合多肽和其用途
US20220372161A1 (en) * 2019-10-08 2022-11-24 Nectin Therapeutics Ltd. Antibodies against the poliovirus receptor (pvr) and uses thereof
KR102370915B1 (ko) 2019-10-22 2022-03-08 단국대학교 천안캠퍼스 산학협력단 폴리오바이러스를 검출하기 위한 등온증폭 반응용 프라이머 세트 및 이의 용도
WO2021163369A2 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
CN115380045A (zh) 2020-02-11 2022-11-22 Hcw生物科技公司 激活调节性t细胞的方法
AU2021219720B2 (en) 2020-02-11 2025-10-02 Immunitybio, Inc. Chromatography resin and uses thereof
US12497462B2 (en) 2020-04-29 2025-12-16 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
KR20230031280A (ko) 2020-06-01 2023-03-07 에이치씨더블유 바이올로직스, 인크. 노화 관련 장애의 치료 방법
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
CN112538108B (zh) * 2020-12-24 2022-06-28 郑州大学 高亲和pvr突变体
CA3229327A1 (en) * 2021-08-20 2023-02-23 Aftab S. Karim Antibodies and antigen binding fragments against cd155 methods of use thereof
CN114005538B (zh) * 2021-11-30 2025-10-28 中国医科大学附属第一医院 Nectin家族和类nectin分子在低级别胶质瘤预后模型中的应用
KR20240156626A (ko) 2022-03-02 2024-10-30 이뮤니티바이오, 인크. 췌장암의 치료 방법
IL314346A (en) 2022-03-15 2024-09-01 Compugen Ltd Antibodies antagonistic to IL-18BP and their use in monotherapy and combination therapy in cancer treatment
CA3261618A1 (en) 2022-09-04 2024-03-07 Nectin Therapeutics Ltd. Humanized Anti-PVR Antibody Drug Conjugates
CN116284395B (zh) * 2022-12-12 2024-11-08 合肥天港免疫药物有限公司 抗cd155的抗体及其应用
WO2024233945A1 (en) * 2023-05-10 2024-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapy of polio virus receptor inhibitors and fucose
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
KR102669477B1 (ko) * 2023-09-04 2024-06-10 재단법인 아산사회복지재단 신규 항-pvr 항체 또는 이의 항원 결합 단편, 및 이의 용도
CN118359711B (zh) * 2024-06-20 2024-10-15 华淞(上海)生物医药科技有限公司 一种抗脊髓灰质炎病毒1型抗体及其制备方法和用途

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5910573A (en) 1992-01-23 1999-06-08 Merck Patent Gesellschaft Mit Beschrankter Haftung Monomeric and dimeric antibody-fragment fusion proteins
CA2137558A1 (en) 1992-07-17 1994-02-03 Wayne A. Marasco Method of intracellular binding of target molecules
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO1995003832A1 (en) 1993-07-30 1995-02-09 Thomas Jefferson University Intracellular immunization
US6294353B1 (en) 1994-10-20 2001-09-25 Morphosys Ag Targeted hetero-association of recombinant proteins to multi-functional complexes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
US6518033B1 (en) * 1998-08-05 2003-02-11 The Research Foundation Of State University Of New York Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment
US6264940B1 (en) * 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
US20030119185A1 (en) 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
MXPA03010804A (es) 2001-06-01 2004-11-22 Cornell Res Foundation Inc Anticuerpos modificados para antigeno de membrana especifico de la prostata y usos de los mismos.
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
EP1481993A1 (en) * 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP3683230A1 (en) 2005-05-12 2020-07-22 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
JP5457671B2 (ja) 2005-07-28 2014-04-02 ノバルティス アーゲー Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
RU2456298C2 (ru) 2005-12-20 2012-07-20 ЭсБиАй БАЙОТЕК КО., ЛТД. Антитело против ilt17
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
FR2909092B1 (fr) 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
SI2131860T1 (sl) 2007-03-20 2014-02-28 Eli Lilly And Company Protitelesa proti sklerostinu
AU2009233708B2 (en) 2008-04-09 2015-06-04 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
JP5686361B2 (ja) * 2010-01-28 2015-03-18 国立大学法人 筑波大学 可溶型ｃｄ１５５タンパク質を用いた癌の検出方法
NZ728016A (en) 2010-12-08 2020-06-26 Abbvie Stemcentrx Llc Novel modulators and methods of use
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
EP2800196B1 (en) 2011-12-27 2018-09-26 LG Chem, Ltd. Lithium secondary battery and preparation thereof
CN104602707A (zh) 2012-06-06 2015-05-06 昂考梅德药品有限公司 调节hippo途径的结合剂及其应用
CA2892831A1 (en) 2012-12-04 2014-06-12 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
RU2019109456A (ru) 2013-02-22 2019-04-10 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые конъюгаты антител и их применения
SI3021869T1 (sl) 2013-07-16 2020-10-30 F. Hoffmann-La Roche Ag Postopki zdravljenja raka z uporabo antagonistov in inhibitorjev TIGIT, ki se vežejo na os PD-1
EP3038659A4 (en) 2013-08-28 2017-07-26 AbbVie Stemcentrx LLC Engineered anti-dll3 conjugates and methods of use
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
WO2015142303A1 (en) 2014-03-18 2015-09-24 Gokmen Vural A solution for extending shelf life of ready-to-eat fresh fruits and/or vegetables and an application method thereof
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
US10906987B2 (en) 2016-03-01 2021-02-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (PVR)

Also Published As

Publication number Publication date
NZ745564A (en) 2024-12-20
JP6966176B2 (ja) 2021-11-10
AU2024201912A1 (en) 2024-04-11
US20210115150A1 (en) 2021-04-22
WO2017149538A1 (en) 2017-09-08
CA3015619A1 (en) 2017-09-08
AU2017228055B2 (en) 2024-04-04
JP2019511212A (ja) 2019-04-25
KR20250065434A (ko) 2025-05-12
CN109071666B (zh) 2022-06-28
IL296874A (en) 2022-11-01
IL261200B (en) 2022-11-01
IL261200B2 (en) 2023-03-01
RU2018134065A (ru) 2020-04-01
MX2022014867A (es) 2023-03-06
KR20180133399A (ko) 2018-12-14
RU2756275C2 (ru) 2021-09-29
IL261200A (en) 2018-10-31
ES2903280T3 (es) 2022-03-31
CN109071666A (zh) 2018-12-21
US20200040092A1 (en) 2020-02-06
BR112018067522A2 (pt) 2019-02-05
AU2017228055A1 (en) 2018-09-20
KR102812377B1 (ko) 2025-05-23
EP3423495B1 (en) 2021-10-20
EP4043492A1 (en) 2022-08-17
CO2018010538A2 (es) 2018-12-14
SG11201807437XA (en) 2018-09-27
US10906987B2 (en) 2021-02-02
EP3423495A1 (en) 2019-01-09
US20240018257A1 (en) 2024-01-18
RU2018134065A3 (es) 2020-07-20

Similar Documents

Publication Publication Date Title
MX2018010445A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
ECSP19072235A (es) Anticuerpos anti-ILT4 y fragmentos de unión a antígeno
CY1121539T1 (el) Ειδικοι για κλαυδiνη-6 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων
BR112016014731A2 (pt) Anticorpos anti-baff
CL2018000378A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos
DOP2019000165A (es) Anticuerpos anti-ox40 y sus usos
CO2018000244A2 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
MX2016010856A (es) Metodo.
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
CO2017006740A2 (es) Anticuerpos anti–cd79b
MX2017001599A (es) Anticuerpos novedosos y sus usos.
MX2017001597A (es) Anticuerpos anti-pd-l1.
ECSP17012781A (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
CR20180225A (es) Anticuerpo anti-tigit y métodos de uso
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
BR112017011914A2 (pt) ?antígeno de maturação de célula b de direcionamento de anticorpos e métodos de uso?
MX377753B (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
BR112016022841A8 (pt) Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
CL2019003557A1 (es) Anticuerpos anti-trkb.
BR112019020412A2 (pt) composições e métodos para detectar câncer de pulmão
AR113854A1 (es) Anticuerpos anti-cxcr5, composiciones y usos de los mismos
AR099899A1 (es) Anticuerpos y fragmentos anti-vista
BR112017020894A2 (pt) imunoreceptores específicos claudina-18.2 e epítopos de células t